Tivantinib

905854-02-6

C23H19N3O2

DMSO : >= 100 mg/mL (270.69 mM)

Protein Tyrosine Kinase/RTK

Tivantinib is a novel and highly selective c-Met tyrosine kinase inhibitor with K_i of 355 nM. IC50 & Target: Ki: 355 nM (c-Met)^[1] In Vitro: Tivantinib (ARQ 197) selectively inhibits c-Met activity in cell-free and cell-based assays. c-Met-expressing cancer cell lines treated with Tivantinib display either a dose-dependent loss of proliferative capacity or caspase-dependent apoptosis that positively correlates with either ligand-dependent c-Met activity or constitutively active c-Met. To examine the biochemical mode of inhibition of Tivantinib, kinetic analyses are done using recombinant human c-Met in a filtermat-based assay. The K_m of ATP is 50.5+/-2.2 uM, which is similar to the K_m value of ATP. In these kinetic studies, Tivantinib inhibits human recombinant c-Met with a calculated inhibitory constant (K_i) of ca.355 nM. In vitro exposure to Tivantinib inhibits constitutive c-Met phosphorylation in HT29 and MKN-45 cells, and HGF-induced c-Met phosphorylation in MDA-MB-231 and NCI-H441 cells with an IC₅₀ of 100 to 300 nM^[1]. Tivantinib is a low-molecular-weight compound, and is the first in class orally available selective inhibitor of c-Met^[2]. In Vivo: Pharmacodynamically, the phosphorylation of c-Met in human colon xenograft tumors (HT29) is strongly inhibited by Tivantinib (ARQ 197), as assessed by a dramatic reduction of c-Met autophosphorylation 24 hours after a single oral dose of 200 mg/kg of Tivantinib. This same dosage in mice shows that tumor xenografts are exposed to sustained plasma levels of Tivantinib, consistent with the observed pharmacodynamic inhibition of c-Met phosphorylation and inhibition of proliferation of c-Met harboring cancer cell lines. A C_max of 5.73 ug/mL (13 uM), an area under the concentration-time curve of 12.1 ug/mL h, and a t_1/2 of 2.4 hours are measured. Plasma levels of Tivantinib 10 hours after dosing are determined to be 1.3 uM, >3-fold above the biochemical inhibitory constant of Tivantinib for c-Met^[1].